表紙
市場調查報告書

絲裂原活化蛋白激酶 5:開發中產品分析

Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 371939
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
絲裂原活化蛋白激酶 5:開發中產品分析 Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 59 Pages
簡介

本報告提供以絲裂原活化蛋白激酶為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊5。

簡介

  • 調查範圍

絲裂原活化蛋白激酶 5 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Gilead Sciences, Inc.
  • Kyowa Hakko Kirin
  • 武田藥品工業

藥物簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2202TDB

Summary

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is a member of MAP kinase kinase kinase family encoded by MAP3K5 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signaling for determination of cell fate such as differentiation and survival. It plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. It is essential for host defense against a wide range of pathogens. It mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals.

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 9 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Cardiovascular, Central Nervous System, Immunology, Metabolic Disorders, Toxicology, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Oncology and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Drug Toxicity, Hepatic Injury, Inflammation, Myocardial Infarction, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Acute Renal Failure (ARF) (Acute Kidney Injury), Alcoholic Hepatitis, Amyotrophic Lateral Sclerosis, Cardiovascular Disease, Fibrosis, Gastric Cancer, Hepatic Encephalopathy, Pain, Pulmonary Hypertension, Rheumatoid Arthritis, Thrombosis and Unspecified.

The latest report Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)
  • The report reviews Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Overview
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Companies Involved in Therapeutics Development
  • Angion Biomedica Corp
  • Calchan Ltd
  • Chipscreen Biosciences Ltd
  • Enanta Pharmaceuticals Inc
  • FronThera US Pharmaceuticals LLC
  • Gilead Sciences Inc
  • Kyowa Kirin Co Ltd
  • Seal Rock Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Terns Pharmaceuticals Inc
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Drug Profiles
  • ANG-4102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CS-410 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EP-026856 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EP-027315 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-444217 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-459679 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • selonsertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ASK1 for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Fibrosis, Hematological Diseases and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Unspecified Indication - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ASK1 for Myocardial Infarction, Neurodegenerative Diseases and Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRT-015 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Dormant Products
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Discontinued Products
  • Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 08, 2019: PathAI and Gilead show AI-powered pathology research models accurately interpret liver histology in patients with NASH at AASLD 2019
  • Apr 26, 2019: Gilead's selonsertib fails in second Phase III trial for NASH
  • Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-026856 at ILC 2019
  • Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-027315 at ILC 2019
  • Feb 13, 2019: Gilead's selonsertib fails in Phase III STELLAR-4 study for NASH
  • Nov 09, 2018: Seal Rock Therapeutics advancing differentiated ASK1 inhibitor lead candidate SRT-015 in nonalcoholic steatohepatitis (NASH)
  • Nov 09, 2018: Gilead Sciences presents data on Selonsertib at The Liver Meeting 2018
  • Oct 11, 2018: Gilead to present data on Selonsertib at The Liver Meeting 2018
  • Apr 13, 2018: Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress 2018
  • Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017
  • Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016
  • Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease
  • Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Angion Biomedica Corp, H2 2019
  • Pipeline by Calchan Ltd, H2 2019
  • Pipeline by Chipscreen Biosciences Ltd, H2 2019
  • Pipeline by Enanta Pharmaceuticals Inc, H2 2019
  • Pipeline by FronThera US Pharmaceuticals LLC, H2 2019
  • Pipeline by Gilead Sciences Inc, H2 2019
  • Pipeline by Kyowa Kirin Co Ltd, H2 2019
  • Pipeline by Seal Rock Therapeutics Inc, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Terns Pharmaceuticals Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top